Tam-Peli cuts death risk 54% in China

MediLink said Tam-Peli reduced the risk of death by 54 percent versus topotecan in a China phase III trial announced Sept. 13, 2026; equities reaction pending.

China phase III results

The company said the trial enrolled patients with relapsed small-cell lung cancer and showed a statistically significant overall survival benefit for tambotatug pelitecan (Tam-Peli) compared with topotecan. MediLink described the result as statistically significant; the announcement named Roche as a development collaborator.

MediLink said the study was conducted in a Chinese patient population and that Tam-Peli also showed improvements on secondary endpoints, without providing an exact figure for progression measures in its initial release. The company announced the results on Sept. 13, 2026; further detail and full datasets have not yet been released.

If regulators accept the submitted data, Tam-Peli could alter second-line treatment options in relapsed small-cell lung cancer and shift the commercial outlook for MediLink and Roche’s collaboration. Investors typically reassess valuation on positive pivotal readouts for oncology assets; market moves will depend on safety details and the size of the effect across predefined subgroups.

Market participants will watch for regulatory filings and full data disclosure within 90 days of the Sept. 13, 2026 announcement.